ArticleMedicine2026
Risk factors for TIVAD-related venous thrombosis in Chinese breast cancer patients undergoing chemotherapy: A single-center retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Totally implantable venous access devices (TIVADs) are widely used in breast cancer patients receiving chemotherapy; however, catheter-related thrombosis can occur and may be asymptomatic. This study aimed to examine the prevalence and associated risk factors of TIVAD-related venous thrombosis in breast cancer patients undergoing chemotherapy. We conducted a retrospective analysis of 143 consecutive breast cancer patients who received TIVAD implantation at our hospital from March 2022 to February 2023. Routine color Doppler ultrasonography of catheter-associated veins was conducted following the conclusion of all chemotherapy cycles and prior to the removal of the TIVAD. Patients were classified into thrombosis and non-thrombosis cohorts. Variables relating to patients, treatments, and catheters were compared among groups. TIVAD-related venous thrombosis was detected in 37 of 143 patients (25.87%); all cases were asymptomatic and identified by routine ultrasound screening prior to TIVAD removal. The median TIVAD retention time was 148 days. A significant difference in TIVAD material was observed between groups (P < .05). No significant differences were found in age, body weight, tumor-node-metastasis (TNM) stage, puncture site, timing of chemotherapy, chemotherapy regimen category, catheter tip position, or TIVAD retention period (all P > .05). Asymptomatic TIVAD-associated venous thrombosis is prevalent among breast cancer patients undergoing chemotherapy. TIVAD material may be linked to thrombosis risk, although the duration of TIVAD retention was not substantially correlated with thrombosis in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.